Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, shared a post on X:
“Another Target Cancer Molecular Tumor Board.
Helping patients with rare cancers. Experts from MD Anderson, Dana Farber/Harvard, UCSD, MCW etc. TRACK is the first fully remote precision trial across USA.
Pleased to serve as PI and work with this exceptional team.
As you know, I really like idea of functional testing. However this trial was started several years ago and is based on NGS.”
Other articles about MD Anderson on OncoDaily.